scholarly journals Attitudes towards genetic susceptibility testing for Alzheimer’s disease dementia in cognitively normal adults: A survey study

2020 ◽  
Vol 16 (S3) ◽  
Author(s):  
Larissa A Masselink ◽  
Leonie NC Visser ◽  
Solange Cleutjens ◽  
Sven J van der Lee ◽  
Jetske van der Schaar ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Genetic Susceptibility ◽  
Susceptibility Testing ◽  
Survey Study ◽  
Cognitively Normal ◽  
Genetic Susceptibility Testing ◽  
Normal Adults ◽  
Alzheimer’S Disease Dementia

scholarly journals P1-214: False Reassurance Following Genetic Susceptibility Testing for Alzheimer's Disease: Evidence from the REVEAL Study

2011 ◽  
Vol 7 ◽  
pp. S179-S180
Author(s):  
Margaret Bradbury ◽  
Clara Chen ◽  
Denise Lautenbach ◽  
Kurt Christensen ◽  
L. Cupples ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Genetic Susceptibility ◽  
Susceptibility Testing ◽  
Reveal Study ◽  
Genetic Susceptibility Testing

scholarly journals P2-240: Development of a new scale measuring psychological impact of genetic susceptibility testing for Alzheimer's disease

2008 ◽  
Vol 4 ◽  
pp. T442-T442 ◽  
Author(s):  
Robert A. Stern ◽  
Winston W. Chung ◽  
Clara A. Chen ◽  
L. Adrienne Cupples ◽  
J. Scott Roberts ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Genetic Susceptibility ◽  
Susceptibility Testing ◽  
Psychological Impact ◽  
Genetic Susceptibility Testing

scholarly journals Test–retest characteristic of [18F]MK-6240 quantitative outcomes in cognitively normal adults and subjects with Alzheimer’s disease

2019 ◽  
Vol 40 (11) ◽  
pp. 2179-2187 ◽  
Author(s):  
Cristian Salinas ◽  
Talakad G Lohith ◽  
Ajay Purohit ◽  
Arie Struyk ◽  
Cyrille Sur ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Brain Parenchyma ◽  
Binding Potential ◽  
Cognitively Normal ◽  
Future Studies ◽  
Arterial Blood ◽  
Quantitative Metrics ◽  
The Brain ◽  
Normal Adults

[18F]MK-6240 is a selective, high-affinity PET radiotracer for imaging neurofibrillary tangles (NFT) in Alzheimer’s disease (AD). Herein, we report test–retest (T–RT) reproducibility of [18F]MK-6240 in AD and healthy volunteers (HV). Twelve subjects with AD and three cognitively normal HV were enrolled in the study and dynamically scanned for 150 min with [18F]MK-6240 under a T–RT protocol. Two radioactivity doses were investigated: 165 ± 3 MBq (n = 6) and 300 ± 40 MBq (n = 9). Serial arterial blood samples were taken for each scan to obtain metabolite-corrected input functions. Following intravenous administration of [18F]MK-6240, the tracer rapidly partitioned into the brain and its heterogenous distribution pattern was consistent with known NFT pathology in AD. In contrast, uptake in HV was low and uniform across the brain parenchyma. Across all subjects, average T–RT variabilities in NFT-rich regions were ∼21%, ∼14% and ∼6% for various quantitative metrics: total distribution volume (VT), binding potential (BPND), and standardized uptake ratio (SUVR90–120), respectively. No significant differences in SUVR T–RT variability were observed between the high and low injected radioactivity groups (5.6% and 6.1%, respectively). This work suggests [18F]MK-6240 has adequate SUVR T–RT characteristics supporting the use of this outcome in future studies.

Sign in / Sign up

Export Citation Format

Share Document